BioTuesdays

Category - News

Qualigen Therapeutics

Qualigen acquires majority stake in NanoSynex

Qualigen Therapeutics (NASDAQ:QLGN) completed the acquisition of a majority stake in NanoSynex, an Israeli-based developer of next generation diagnostics technology. In a statement, Michael Poirier, chairman and CEO of...

Connect-Biopharma-Logo

Cantor starts Connect Biopharma at OW; PT $5

Cantor Fitzgerald initiated coverage of Connect Biopharma (NASDAQ:CNTB) with an “overweight” rating and a discounted cash flow-based price target of $5. The stock closed at 75 cents on June 1. “We think that...

Ocugen

Cantor starts Ocugen at OW; PT $4.50

Cantor Fitzgerald launched coverage of Ocugen (NASDAQ:OCGN) with an “overweight” rating and price target of $4.50. The stock closed at $2.17 on June 1. Ocugen is a clinical-stage biotechnology company focused on...

Gracell Biotechnologies

Cantor starts Gracell Biotechnologies at OW; PT $20

Cantor Fitzgerald initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with an “overweight” rating and $20 price target. The stock closed at $3.29 on May 31. Gracell is a clinical-stage biopharmaceutical company...

NexImmune-Logo

BTIG starts NexImmune at buy; PT $5

BTIG initiated coverage of NexImmune (NASDAQ:NEXI) with a “buy” rating and price target of $5. The stock closed at $2.28 on May 31. NexImmune exploits signals naturally provided by dendritic cells (DCs) to activate...

PepGen Logo

SVB Securities starts PepGen at OP; PT $40

SVB Securities launched coverage of PepGen (NASDAQ:PEPG) with an “outperform” rating and $40 price target. The stock closed at $10.88 on May 27. PepGen is a clinical-stage biotech advancing its enhanced delivery...

Liquidia Logo

BTIG starts Liquidia at buy; PT $14 

BTIG initiated coverage of Liquidia (NASDAQ:LQDA) with a “buy” rating and $14 price target. The stock closed at $4.07 on May 27. Analyst Julian Harrison writes that Liquidia has brought its lead candidate, YUTREPIA, to...